Biotechnology · Pasadena, California, United States
$7.21
-8.91% (-$0.71)2026-07-02
Smart-Money SignalNeutral · 45/100— Insider open-market flow is flat over 90 days
Net Income-$2.0M
EPS$-0.18
Market Cap$83.9M
Price Performance
Historical data including institutional events
Company Profile
G
Geordan Pursglove
CEO & Executive Director
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The companyâs LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
- Founded
- 2005
- Employees
- 2
- Headquarters
- Pasadena, California, United States
- Website
- lixte.com
Peer ComparisonRevenue ($B)
▾Loading company sections...